GgoogleDE first seen 3 d ago, last 3 d ago, peak #7
Argenx reports phase 2 celiac win for $2.2B drug
Original: argenx
Argenx, the Dutch-Belgian biotech best known for Vyvgart, has reported positive phase 2 results for a drug with an estimated $2.2 billion sales opportunity in celiac disease, according to Fierce Biotech. The company says it now plans to move the treatment into pivotal trials, keeping momentum behind its expansion beyond immunology flagship indications.
Why now: Investors and biotech watchers are tracking Argenx's pipeline expansion after the encouraging phase 2 celiac disease data.
Evidence
- Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run · Fierce Biotech
API: https://socialmediatrends-api.osmike.com/v1/trends/1503924